DeCART Therapeutics
DeCART Therapeutics focuses on improving CAR T cell therapies for cancer. They modify T cell biology ex vivo using small molecules to control protein levels. This approach creates drug-enhanced CAR T cells, aiming for better phenotypes and patient outcomes. Core technologies include small molecule modulation and ex vivo T cell engineering to tailor CAR T cells for therapies. The company operates in the biotech space, targeting cancer immunotherapy and collaborating with researchers.
DeCART Therapeutics
DeCART Therapeutics focuses on improving CAR T cell therapies for cancer. They modify T cell biology ex vivo using small molecules to control protein levels. This approach creates drug-enhanced CAR T cells, aiming for better phenotypes and patient outcomes. Core technologies include small molecule modulation and ex vivo T cell engineering to tailor CAR T cells for therapies. The company operates in the biotech space, targeting cancer immunotherapy and collaborating with researchers.